A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma

Background & aims: This phase Ib/II trial evaluated the safety and efficacy of capmatinib in combination with spartalizumab or spartalizumab alone in patients with advanced hepatocellular carcinoma (HCC). Methods: Eligible patients who had progressed or were intolerant to sorafenib received esca...

Cijeli opis

Bibliografski detalji

Glavni autori:	Armando Santoro, Eric Assenat, Thomas Yau, Jean-Pierre Delord, Michela Maur, Jennifer Knox, Stephane Cattan, Kyung-Hun Lee, Gianluca Del Conte, Christoph Springfeld, Elisa Leo, Alexandros Xyrafas, Lauren Fairchild, Feby Mardjuadi, Stephen L. Chan
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2024-04-01
Serija:	JHEP Reports
Teme:	Capmatinib Spartalizumab Hepatocellular carcinoma MET anti-programmed death-ligand 1
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2589555924000223
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!